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ticoids and antiprogestins. Dissociation of these 
activities was illustrated by M. Moguilewsky (Ro- 
mainville). 
Whereas 17a-propinyl derivatives with large 
aromatic substitutions in C-llfi had high affinity 
for both the progesterone and glucocorticoid 
receptors, suggesting the presence of a hydropho- 
bic pocket of IO-12 A, analogous substitutions in 
C-10 yielded ligands specific for the glucoreceptor 
that were, however, active only in vitro. A spiro- 
pentyl ether in C-17, in the presence of an 11,&e- 
methylthiophenyl, gave the compound RU 46556 
with good antiprogestin activity in vivo and 
negligible antiglucocorticoid action. 
The antiprogestin action of TX 380 (17,& 
acetoxy-Sty, 17a-pregn-2-en-20-yne) on endome- 
trial proliferation in the rabbit, and pregnancy 
maintenance in the rat, does not appear to proceed 
by interaction with the progesterone receptor. This 
compound also exhibits weak androgenicity and 
estrogenicity in vivo (R. Delansorne, Monaco). 
M. Nakamura (Osaka) reported the antimine- 
ralocorticoid activity of 11,lZdehydropregnanes 
with a 17y-spirolactone function, synthesized in 
Shionogi Research Laboratories. The affinity of 
compound no.840023 (3-(17,&hydroxy-3-oxoan- 
drosta-I ,4,6,11-tetraen-17a-yl)propionic acid 7: 
lactone) for the mineraloreceptor was twice that of 
spirolactone but the product also exhibited weak 
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affinity for the androgen and the progesterone 
receptors. 
V. Bissery from J.P. Mornon’s laboratory 
(Paris) illustrated the very strong structural simi- 
larity among steroid-binding domains of hormone 
receptors and of carrier proteins (transcortin, 
thyroid binding globulin) using the ‘hydrophobic 
cluster analysis’. This method permits prediction 
of the secondary structure and was also used to 
analyse the zinc finger and the steroid-binding site 
on the receptor. 
J.A. Carlstedt-Duke (Huddinge) presented the 
latest advances in the structure/function relation- 
ships of the rat liver glucocorticoid receptor. The 
monomeric (94 kDa) receptor, purified by a simple 
two-step procedure from rat liver, binds specifical- 
ly to the glucocorticoid response elements in the 
mouse mammary tumour virus DNA. Met-622, 
and Cys-754 and -656 in the C-terminal steroid- 
binding domain could be covalently labelled by 
dexamethasone mesylate and/or photolabelled by 
triamcinolone acetonide. Since the N-terminal 
DNA-binding domain of the purified receptor ex- 
hibited IO-fold lower affinity for DNA than the 
native receptor and did not require zinc, the 
cytosolic receptor may be subject to post- 
translational modifications in vivo. 
C. Chang (Chicago) has cloned the cDNAs of 
rat testis and human androgen receptors. The 
DNA-binding domain of these receptors exhibited 
almost 80% sequence homology with that of the 
progesterone, gluco- and mineralocorticoid recep- 
tors but only 40-50% homology with vitamin D, 
thyroid hormone and estrogen receptors. The C- 
terminal domain of the cloned receptor was highly 
specific to androgens, and polyclonal antibodies 
against the N-terminal domain recognized proteins 
obtained by the in vitro expression of cDNA for 
the androgen receptor. 
Using a synthetic glucocorticoid cortivazol, and 
the antagonist RU 38486, E.B. Thompson (Gal- 
veston) demonstrated the presence of two binding 
sites on the glucoreceptor in CEM C7 leukemic 
cells. The high-affinity site with & lo- * M could 
be specifically blocked by either RU 38486 or 
dexamethasone mesylate at a time when cortivazol 
saturated the site with Kd lo- lo M. This could ex- 
plain earlier observations where antagonist- 
specific receptors have been reported in the 
estrogen and mineralcorticoid systems. In addi- 
2 
tion, the steroid-binding site on the glucoreceptor 
in HTC cells seems to contain two sulphydryl 
groups although reduced thiols are apparently not 
required for steroid binding (S.S. Simons, 
Bethesda). 
M.K. Agarwal (Paris) demonstrated that the 
chromatographic profile of the gluco- and the 
mineraloreceptors from a variety of tissues 
depended upon the steroid occupying the receptor. 
Purification of the mineraloreceptor saturated 
with various agonists and antagonists, however, 
appeared to reveal a similar fundamental unit dur- 
ing chromatographic analysis. Therefore, some 
sort of post-translational modifications of the 
receptor appear to be operative in vivo, as noted in 
earlier presentations. None of the known functions 
of the receptor (stability, activation) could be call- 
ed specific to the hormone, since they were in- 
discriminately altered by agonists as well as 
antagonists. Rather, discrimination between the 
agonist and the antagonist seemed to proceed on 
the steroid-binding domain of the glucoreceptor, 
recalling the possibility of different binding sites. 
J.W. Funder (Melbourne) speculated that the 
discrimination between the action of gluco- and 
mineralocorticoid in bifunctional organs (kidney) 
could occur prior to receptor occupancy by the 
steroid at the level of microsomal enzymes such as 
1 I&hydroxysteroid dehydrogenase, and possibly 
aromatase. Inhibitors of such enzymes could con- 
stitute new targets for antihormone research. 
Multiple molecular targets of antihormone ac- 
tion were discussed by J.P. Raynaud (Paris). The 
antiandrogen anandron inhibits androgen uptake 
by the prostate by interaction with the androgen 
receptor; it modifies Sa-reductase activity in 
human prostate microsomes; it inhibits 17cu- 
hydroxylase and 17,20-lyase activities in rat 
testicular microsomes; it competes competitively 
for hexobarbital hydroxylase and, in a more com- 
plex manner, with benzophetamine N-demethyl- 
ase. Preliminary experiments indicate that it can 
also interact with the active site on cytochrome 
P450. 
R. Dolcek (Ostrava) compared the inhibition of 
endocrine function by the fungistatic drug 
ketoconazole that binds to cytochrome P450 with 
the fungicidal drug terbinafine that does not, 
although both materials inhibit steroid synthesis in 
vivo. 
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Receptor-mediated action of androgens was 
demonstrated by the down-regulation of the 
estrogen receptor by dihydrotestosterone in 
ZR-75-1 human breast cancer cells which was 
reversed by the antiandrogen Flutamide (F. 
Labrie, Quebec). These authors also recalled that 
‘progestins’ currently used as ‘antiandrogens’ can 
induce androgen-dependent gene expression. 
A. Takeda (Nagoya) stressed that ‘antihor- 
mones’ may be endowed with both agonist- and 
antagonist-type action. Like estradiol, but to a 
lesser extent, both Tamoxifen and LY117018 
stimulate the induction of a 97 kDa glycoprotein 
(LISP-l) in rat uterine epithelial cells although the 
nature of the protein is not identical. The induc- 
tion of USP-1 by estrogens was significantly 
diminished by both antiestrogens. 
The issues raised by long-term treatment with an 
antihormone were elucidated by G.P. Chrousos 
(Bethesda). The antiglucocorticoid effect of RU 
38486 was exploited in the treatment of Cushing’s 
disease due to an excess of endogenous glucocor- 
ticoids. Under these conditions, adrenal insuffi- 
ciency may arise during chronic treatment and may 
even lead to hypokalemic alkalosis and hyperten- 
sion, as well as erythema multiforme, menstrual 
abnormalities, and gynecomastia. The acute an- 
tiprogestin action of RU 38486, exploited in the in- 
terruption of pregnancy, may be associated with 
the elevation of plasma ACTH and cortisol. 
In conclusion, this workshop highlighted several 
important considerations in receptor research. 
First, the primary receptor gene product appears to 
undergo various post-translational modifications 
in vivo. Thus, the cloning of receptor genes, and 
the genesis of functional products in vitro, neither 
reflect the actual situation in vivo nor obviate the 
need for organismal approach to understanding 
hormone action. Indeed, the common features be- 
tween different classes of steroid hormone recep- 
tors may become apparent only during three- 
dimensional analysis. Second, receptors for several 
classes of steroid hormones may have more than 
one binding site that, among other factors, may 
give the impression of receptor heterogeneity. 
Third, no property of the receptor may be called 
causal to the action of any given hormone and it is 
not possible to distinguish between agonists and 
antagonists merely by studying a particular recep- 
tor function. Finally, since receptors function 
within an integrated system in the cell, one must 
take into account the availability of their cognate 
hormone which is both a substrate and a product 
of specific enzymes. Such enzymes can also in- 
fluence expression of antihormone action. 
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